Episodes (Page 26)
✨
Analyzes masculinity and testosterone-driven politics in elections
✨
Dr. Jenny Schuetz discusses structural shifts and trends in the housing market
Jenny Schuetz
✨
Brand strategy examined to understand why some brands maintain strong reputations while others deteriorate
✨
Democratic Party leadership blame game analyzed with focus on Biden's decision to run versus Harris's approach
✨
Sectors expected to see biggest gains and losses under Trump administration identified
✨
Podcast's role and influence in the 2024 election landscape examined
✨
Historians Dr. Lindsay Chervinsky and Dr. Timothy Naftali assess threats Trump poses to democracy
✨
Uber's potential acquisition of Expedia analyzed as strategic move toward integrated travel platform
✨
Final campaign developments and Election Day preparations discussed with key races analyzed
✨
Meta's AI capabilities, Microsoft's earnings disappointment, and YouTube spinoff proposal discussed
✨
Tarek Mansour, CEO of Kalshi, discusses the regulated prediction market platform's legal battle to enable election betting
Ed Elson
✨
Scott Galloway explores themes of anxiety in modern society and personal well-being
✨
Aswath Damodaran provides valuation analysis on whether Boeing and Intel can recover from current challenges
Aswath Damodaran
✨
Ian Bremmer from Eurasia Group analyzes major geopolitical forces shaping the current global landscape
Ian Bremmer
✨
Scott examines corporate board composition, age diversity, and governance responsibilities
✨
Scott Galloway and Jessica Tarlov break down final week campaign activities including Harris star-studded rallies and Trump's Joe Rogan appearance
✨
Scott argues Boeing could be a buy despite disappointing earnings due to long-term thinking and pension settlement potential
✨
Scott Galloway publicly endorses Vice President Kamala Harris for the 2024 election
Vice President Kamala Harris
✨
Angela Duckworth, psychologist and author of 'Grit,' discusses attributes of gritty people and resilience factors
Angela Duckworth
✨
Scott analyzes Pfizer's activist investor battle with Starboard and reasons for optimism about stock recovery